TerminatedEarly Phase 1NCT01413451

Amatuximab for High Mesothelin Cancers

Studying Pleural mesothelioma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Cancer Institute (NCI)
Principal Investigator
Raffit Hassan, M.D.
National Cancer Institute (NCI)
Intervention
Amatuximab (MORab-009)(drug)
Enrollment
7 enrolled
Eligibility
18-100 years · All sexes
Timeline
20112013

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01413451 on ClinicalTrials.gov

Other trials for Pleural mesothelioma

Additional recruiting or active studies for the same condition.

See all trials for Pleural mesothelioma

← Back to all trials